Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers

计划入组 20 人 · 首次发布于 2010 年 8 月 6 日

Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients

计划入组 156 人 · 首次发布于 2014 年 4 月 17 日

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

计划入组 250 人 · 首次发布于 2024 年 12 月 2 日

anti-CD3/CD19 bispecific antibody ( Curon Biopharmaceutical )

Epilepsy(Merdury Biopharmaceutical )

CS-02(Zhongshan Hengdong Biopharmaceutical)

CURON BIOPHARMACEUTICAL (AUSTRALIA) CO PTY LTD

Australia

Sino Biopharmaceutical Limited

China

Asklepios Biopharmaceutical, Inc.

United States

Merck Finalizes Acquisition of Curon Bio's Bispecific Antibody CN201 for B-Cell Malignancies

Merck & Co. Acquires Curon Bio's Bispecific T-Cell Engager for $1.3 Billion

Merck Expands Oncology Pipeline with $3.2B Deal for LaNova's Bispecific Antibody